Correction: The "First BPC-157 RCT" Is Not a Real Trial

The correction above matters more than the original story, so it is worth being precise about what happened — both because readers deserve to know what we got wrong, and because the underlying trick is one that anyone researching peptides will run into.

What the registration batch actually looks like

Eight registrations share one sponsor (Hudson Biotech), one site (Peking University Shenzhen Hospital), start dates clustered on and around February 2, 2026, and a single central contact email on a domain that does not match the sponsor name. None has been updated since spring 2026, and none has posted results.

Two of them disclose their own nature. NCT07487363, a TB-500 cardiovascular study, begins its Brief Summary with the sentence "This fictional study is an example of a ClinicalTrials.gov-style record."^[2] NCT07481734, a tesamorelin liver-fat study, carries "(Mock Study)" directly in its registered title.^[3] Two more reproduce real Eli Lilly programmes — one is titled as SURMOUNT-1, an actual tirzepatide trial, and another uses the internal compound code for retatrutide.

The remaining records in the batch — BPC-157, GHK-Cu, MOTS-c, and Melanotan II — carry no disclaimer at all. Read on its own, the BPC-157 entry looks like a well-designed Phase 2 study: randomized, double-blind, placebo-controlled, 120 participants, a specific musculoskeletal endpoint. That is why we covered it. Read alongside its seven siblings, it is not credible.

Why a registry listing is not evidence

ClinicalTrials.gov is a registry, not a regulator. Sponsors submit their own records, and while the site applies quality-control checks, a listing is fundamentally a claim that someone intends to run a study — not verification that the study exists, that it is enrolling, or that any oversight body reviewed it. The BPC-157 record was also flagged in the registry as not FDA-regulated, meaning no U.S. Investigational New Drug application governed it.^[1]

This is the practical lesson, and it generalises well beyond BPC-157: an NCT number is not a credential. When a vendor or clinic cites one, the questions worth asking are who the sponsor is, how many sites are involved, whether the sponsor has any other registrations, and whether results were ever posted. In this case, one search of the sponsor's other filings was enough.

Why we wanted this to be real

BPC-157 has been one of the most popular peptides in wellness and biohacking communities for years. People use it for tendon injuries, gut healing, joint pain, and a half-dozen other conditions. Online forums are full of personal testimonials. Clinics have prescribed it. Athletes have used it for recovery.

But here is the uncomfortable truth that has followed BPC-157 for three decades: every piece of human evidence to date has been anecdotal or uncontrolled. The three published human studies — totaling roughly 30 participants — had no placebo groups, no blinding, and all came from the same lead author.^[8] That is not the kind of evidence that tells you whether something actually works or whether people are experiencing placebo effects, natural healing timelines, or confirmation bias.

What BPC-157 does have is a substantial body of animal research — over 100 published studies showing effects on tendon repair, gastrointestinal healing, nerve recovery, and inflammation across rats, mice, and rabbits.^[4] Those results are genuinely promising. But animal studies are a starting point, not proof. Many compounds that look extraordinary in rodents fail when tested rigorously in humans.

That gap is exactly why a registered, placebo-controlled, blinded trial in a musculoskeletal indication looked like such welcome news — and, in hindsight, why it warranted more scrutiny than we gave it. A finding that fits the story you expect is the one to check hardest.

The evidence gap is unchanged

To understand why this correction matters, consider the current state of BPC-157 research. The preclinical literature is extensive — but it comes with an important asterisk.

The overwhelming majority of BPC-157 studies originate from a single laboratory: Predrag Sikiric and colleagues at the University of Zagreb, Croatia.^[6][4] This group has done foundational work, and their findings are consistent across dozens of animal models. But in science, independent replication is what separates promising hypotheses from established facts. For BPC-157, that independent replication has been limited. One notable exception is Chang et al. at Chang Gung University in Taiwan, who confirmed tendon healing mechanisms in vitro — but full in vivo replication from independent labs remains sparse.^[7]

A 2025 systematic review confirmed what most honest assessments of BPC-157 conclude: the evidence base is overwhelmingly preclinical, and controlled human data is essentially nonexistent.^[8]

Nothing about this correction changes that picture — it restores it. For a full breakdown of what the current evidence does and does not show, see our BPC-157 profile. For a closer look at the wider pattern of single-sponsor registrations, see our companion piece on research peptides and registered trials.

How we got it wrong

We reported a registry record as a trial. The record was internally plausible — a real-looking design, a real hospital, a real NCT number — and we did not check the sponsor's other filings before publishing. One search would have surfaced a sibling record announcing itself as fictional in its first sentence.

The specific failure is worth naming, because it is the same failure that peptide marketing relies on: we treated a database entry as though someone had vetted it. Registration requires a submission, not evidence. We have added the sponsor-portfolio check to our research methodology for any registry-sourced claim.

We are leaving this article at its original URL, with its original publication date visible, rather than deleting it. A correction that disappears is not a correction.

What this means for you

If you are currently using BPC-157, or considering it, here is where things actually stand.

No credible BPC-157 trial is underway that we can identify. Anyone citing "the BPC-157 clinical trial" as a reason to buy is very likely pointing at this same registration, or at one like it. Ask which NCT number, then look up who registered it and what else they have registered.

The evidence base is preclinical, and that has not changed. The animal data is genuinely promising. The human data is three small uncontrolled studies from one lab. If you are using BPC-157, you are making a decision based on early-stage science and personal risk tolerance, not on clinical evidence.

The regulatory picture moved, but not in the direction of proof. In July 2026 an FDA advisory committee recommended BPC-157 for the 503A compounding list — over the objection of FDA's own reviewers, who argued the substance is not well characterised. That is a compounding-access question, not an efficacy finding, and FDA has not acted on it.

Talk to a provider. If you are interested in BPC-157 for a specific condition, the best step is a conversation with a knowledgeable healthcare provider who can help you weigh the current evidence, assess your individual risk profile, and monitor you appropriately.

---

References

1. [1]

   ClinicalTrials.gov (sponsor: Hudson Biotech). “BPC 157 for Acute Hamstring Muscle Strain Repair.” 2026. LinkRegistered trial (no results)

   NCT07437547. Listed as recruiting; last updated February 27, 2026, with no results. We no longer treat this record as evidence of a real trial: it belongs to a batch of eight registrations from the same sponsor, at the same single site, two of which state in their own submitted text that they are fictional or mock records. See the correction at the top of this article.

2. [2]

   ClinicalTrials.gov (sponsor: Hudson Biotech). “TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD.” 2026. LinkRegistered trial (no results)

   NCT07487363. The registry record's own Brief Summary opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Same sponsor and site as the BPC-157 registration. Verified against the ClinicalTrials.gov API on August 15, 2026.

3. [3]

   ClinicalTrials.gov (sponsor: Hudson Biotech). “Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study).” 2026. LinkRegistered trial (no results)

   NCT07481734. "(Mock Study)" appears in the registered Brief Title. Same sponsor and site as the BPC-157 registration. Verified against the ClinicalTrials.gov API on August 15, 2026.

4. [4]

   Sikiric P, Hahm KB, Blagaic AB, et al.. “Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response: progress, achievements, and the future.” Gut Liver. 2020. 14(2):153–167 DOI PubMedReview

   Comprehensive review of BPC-157 mechanisms and animal data from the primary research group (University of Zagreb). Covers cytoprotection, angiogenesis, and multi-organ effects across dozens of animal models.

5. [5]

   Gwyer D, Wragg NM, Wilson SL. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell Tissue Res. 2019. 377:153–159 DOI PubMedReview

   Independent review (Loughborough University, UK) of BPC-157's musculoskeletal healing evidence. Confirms promising preclinical signals but highlights the absence of human clinical data.

6. [6]

   Sikiric P, Petek M, Rucman R, et al.. “A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC.” J Physiol Paris. 1993. 87:313–327 DOI PubMedpreclinical

   Foundational paper describing BPC-157's isolation from gastric juice and initial protective effects in rat models. Origin of three decades of subsequent research.

7. [7]

   Chang CH, Tsai WC, Lin MS, et al.. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011. 110:774–780 DOI PubMedpreclinical

   Key independent replication from Chang Gung University (Taiwan). Confirmed BPC-157's tendon healing mechanisms in vitro — one of the few validations outside the Zagreb lab.

8. [8]

   Vasireddi A, Nguyen DD, Thomas JD, et al.. “BPC-157: a systematic review of clinical and preclinical evidence.” Altern Ther Health Med. 2025. DOISystematic review

   Systematic review confirming that the overwhelming majority of BPC-157 evidence is preclinical, with minimal controlled human data. Highlights the single-lab concentration of research.

9. [9]

   U.S. Food and Drug Administration. “Investigational New Drug (IND) application.” 2025. Link

   FDA guidance on the IND process required before administering investigational drugs to humans in clinical trials.

---

---

Related content

Peptide

BPC-157

Full research profile covering mechanism, animal evidence, and safety considerations.

News

Kennedy Peptide Reclassification

How regulatory changes could affect BPC-157 access through compounding pharmacies.

Guide

What Are Peptides?

A foundational guide to understanding peptides and their therapeutic potential.

Peptide

TB-500

A related recovery peptide often discussed alongside BPC-157. Research profile and evidence assessment.

News

FDA Enforcement and the Gray Market

How FDA crackdowns on gray-market sellers affect access to research peptides like BPC-157.

---